lagbone.pages.dev

Kelly chibale malaria mosquito

          In this Review, we describe the approaches that have been successful, progress in preclinical and clinical development, and existing challenges.

        1. In this Review, we describe the approaches that have been successful, progress in preclinical and clinical development, and existing challenges.
        2. The findings show that sapanisertib has the potential to protect from, cure and block malaria transmission by killing the human malaria parasite.
        3. Prof Kelly Chibale says the world is failing to take advantage of African genetic diversity, and everyone could be losing out.
        4. Malaria drugs are developed as combination therapies to reduce resistance risk, although the emergence of resistance to individual partner drugs.
        5. Kelly Chibale receives funding from Medicines for Malaria Venture This includes spraying with insecticides and using mosquito nets.

          6. Prof Kelly Chibale says the world is failing to take advantage of African genetic diversity, and everyone could be losing out.!

          New research: Cancer drug with potential to be used against malaria

          A cancer drug currently in clinical trials has shown the potential to protect from, cure and prevent transmission of malaria.

          The breakthrough finding by the University of Cape Town (UCT) researchers, in collaboration with several local and international institutions from the United States, Germany and Spain, offers new hope against a disease that kills over half a million people annually, most severely affecting children under five, pregnant women and patients with HIV.

          The findings were released on 19 October in a new paper, “The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple Plasmodium kinases and lifecycle stages”, published in the journal Science Translational Medicine.

          The first author is Dr Lauren Arendse of the UCT Drug Discovery and Development Centre (H3D), an integrated and interdisciplinary drug discovery research organisation.

          The senior lead author is Profes